secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2023-06-20T23:59:59+00:00
Accession:  0001628280-23-022677
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex shareholders approve equity plan increase, reject preferred stock authorization
--------------------------------------------------------------------------------

- Stockholders approved amendment to 2017 Equity Incentive Plan, increasing shares available by 3.65M.
- Proposal to authorize 5M shares of preferred stock failed (36.2M for, 8.7M against, 181k abstain).
- All eight director nominees elected with over 36M votes for each (largest withheld 8.5M for Steven Rubin).
- Advisory approval of executive compensation passed with 43.6M for, 1.44M against.
- Ratification of Marcum LLP as auditor for FY2023 approved (53.1M for, 3.0M against).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828023022677/0001628280-23-022677-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828023022677/cdxc-20230615.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-022677

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer